Bookrunner Roth Capital Partners helps fund general corporate purposes
By Devika Patel
Knoxville, Tenn., March 4 - BioLineRx Ltd. said it priced a $21 million public offering of American Depositary Shares with a $3.15 million greenshoe. The deal was announced Monday.
The company will sell 8.4 million ADS at $2.50 per ADS. The price per ADS reflects a 14.38% discount to the March 3 closing ADS price of $2.92.
Each ADS represents 10 ordinary shares.
Roth Capital Partners is the bookrunner.
Settlement is expected March 7.
Proceeds will be used for clinical trials and general corporate purposes.
Based in Jerusalem, BioLineRx is a specialized drug development company.
| Issuer: | BioLineRx Ltd.
|
| Issue: | American Depositary Shares
|
| Amount: | $21 million
|
| Greenshoe: | $3.15 million
|
| Shares: | 8.4 million
|
| Price: | $2.50
|
| Warrants: | No
|
| Bookrunner: | Needham & Co.
|
| Co-manager: | Maxim Group LLC
|
| Announcement date: | March 3
|
| Pricing date: | March 4
|
| Settlement date: | March 7
|
| Stock symbol: | Nasdaq: BLRX
|
| Stock price: | $2.92 at close March 3
|
| Market capitalization: | $59.92 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
